Skip Navigation


Annals of Oncology Advance Access originally published online on June 9, 2008
Annals of Oncology 2008 19(10):1706-1712; doi:10.1093/annonc/mdn369
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
19/10/1706    most recent
mdn369v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ménard, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ménard, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

breast cancer

Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

S. Ménard1,*, A. Balsari1,26, E. Tagliabue1, T. Camerini2, P. Casalini1, R. Bufalino2, F. Castiglioni1, M. L. Carcangiu1, A. Gloghini4, S. Scalone5, P. Querzoli6, M. Lunardi6, A. Molino7, M. Mandarà7, M. Mottolese8, F. Marandino8, M. Venturini9, C. Bighin9, G. Cancello10, E. Montagna10, F. Perrone11, A. De Matteis12, A. Sapino13, M. Donadio14, N. Battelli15, A. Santinelli16, L. Pavesi17, A. Lanza17, F. A. Zito18, A. Labriola18, R. A. Aiello19, M. Caruso19, F. Zanconati20, G. Mustacchi21, M. Barbareschi22, M. Frisinghelli23, R. Russo24, G. Carrillo25 and On the behalf of the OMERO group

1 Department of Experimental Oncology
2 Scientific Directorate
3 Department of Pathology, Fondazione IRCCS ‘Istituto Nazionale dei Tumori’, Milano
4 Department of Pathology
5 Division of Medical Oncology, Istituto CRO, Aviano
6 Department of Pathology, Università di Ferrara, Ferrara
7 Department of Medical Oncology, Università di Verona, Verona
8 Department of Pathology, Istituto Tumori Regina Elena, Roma
9 Department of Oncology, Istituto Nazionale Tumori, Genova
10 Division of Medical Oncology, Università degli Studi Federico II, Napoli
11 Clinical Trails Unit
12 Medical Oncology, Istituto Nazionale Tumori, Pascale, Napoli
13 Department of Biomedical Sciences and Human Oncology
14 UO Medical Oncology, Az. Osp. Molinette, Torino
15 OU Medical Oncology
16 Division of Pathology, Ospedale Regionale Torrette, Ancona
17 Division of Medical Oncology, Fondazione Maugeri, Pavia
18 Department of Pathology, Istituto Oncologico, Bari
19 UO Medical Oncology, Humanitas, Centro Catanese di Oncologia, Catania
20 Department of Clinical Sciences
21 Department of Medical Oncology, Ospedale Maggiore, Trieste
22 Department of Pathology
23 Division of Medical Oncology, Ospedale S.Chiara, Trento
24 Department of Pathology, A.O.R.N. ‘San Giovanni di Dio e Ruggi D'Aragona’, Salerno
25 Department of Pathology, Ospedale Cardarelli, Napoli
26 Chair od Immunology, Institute of Pathology, University of Milan, Italy

* Correspondence to: Dr S. Ménard, Fondazione IRCCS ‘Istituto Nazionale dei Tumori’, via G. Venezian, 1, 20133 Milan, Italy. Tel: +39-02-23902571; Fax: +39-02-23903073; E-mail: sylvie.menard{at}istitutotumori.mi.it

Background: The standardization of the HER2 score and recent changes in therapeutic modalities points to the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinoma.

Patients and methods: A multicenter, retrospective study of 1794 primary breast carcinomas diagnosed in Italy in 2000/2001 and scored in HER2 four categories according to immunohistochemistry was conducted.

Results: Ductal histotype, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. HER2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months, HER2 3+ status was associated with higher relapse rates in node-positive and node-negative subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, especially taxanes.

Conclusions: The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HER2 2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.

Key words: HER2, HeceptTest, prognosis, therapy

Received for publication February 25, 2008. Revision received April 22, 2008. Accepted for publication April 28, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.